Why GLP-1s are So Expensive: i-MAK

Resources for the Community

___________________________________________________________________

https://linktr.ee/theplussidezpodcast 

Ro - Telehealth for GLP1 weight management 

https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55

Find Your US Representatives 

https://www.usa.gov/elected-officials 

United States Patent & Trademark Office Website and Email 

https://www.uspto.gov/

usptoinfo@uspto.gov

i-MAK Website

https://www.i-mak.org/

i-MAK Briefs & Reports 

https://www.i-mak.org/resource-type/briefs/

______________________________________________________________________

Tahir Amin, founder of I-MAK, joins us to break down why GLP-1 meds like Ozempic and Mounjaro stay so pricey. We dig into evergreening, patent thickets, and how pharma companies use legal loopholes to delay generics and extend monopolies.

We also explore why some companies spend more on stock buybacks than drug innovation—and what that means for access. If you’ve felt exploited by the system, you’re not alone. But there’s hope. Learn about the policy changes ahead and how you can take action to fight for affordable meds.

Tahir Amin bio:

Tahir Amin is a founder and CEO of the Initiative for Medicines, Access & Knowledge (I-MAK), a nonprofit organisation working to address the systemic inequities in how medicines are developed and distributed. He has over 30 years of experience in intellectual property (IP) law, during which he has practised with two of the leading IP law firms in the United Kingdom and served as IP Counsel for multinational corporations. His work focuses on changing the structural power dynamics that allow health and economic inequities to persist by challenging and re-shaping IP laws and the related global political economy to better serve the public interest.  He is a former Harvard Medical School Fellow in the Department of Global Health & Social Medicine and has served as legal advisor/consultant to many international groups, including the European Patent Office and World Health Organization, as well as testifying before the U.S. Congress on intellectual property and unsustainable drug prices.

Special Guest Co-Host, Amanda Bonello from GLP-1 Collective 

https://glp1collective.org/ _______________________________